Related references
Note: Only part of the references are listed.Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study
Mayu Tochiya et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Yue Fei et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial
Atsushi Tanaka et al.
DIABETES CARE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
Concetta Irace et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)
Takashi Nomiyama et al.
ENDOCRINE JOURNAL (2018)
Clinical Utility of Carotid Ultrasonography in The Prediction of Cardiovascular Events in Patients with Diabetes: A Combined Analysis of Data Obtained in Five Longitudinal Studies
Naoto Katakami et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2018)
Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration
Matthias W. Lorenz et al.
PLOS ONE (2018)
Effect of Tofogliflozin on Body Composition and Glycemic Control In Japanese Subjects with Type 2 Diabetes Mellitus
Shinji Kamei et al.
JOURNAL OF DIABETES RESEARCH (2018)
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Narjes Nasiri-Ansari et al.
CARDIOVASCULAR DIABETOLOGY (2018)
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
Ji Hye Han et al.
DIABETOLOGIA (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial
Kohjiro Ueki et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study
Naoto Katakami et al.
DIABETES THERAPY (2017)
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study
Naoto Katakami et al.
DIABETES THERAPY (2017)
Clustering of cardiovascular risk factors and carotid intima-media thickness: The USE-IMT study
Xin Wang et al.
PLOS ONE (2017)
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
Fumika Shigiyama et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)
Tomoya Mita et al.
DIABETES CARE (2016)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Muhammad Abdul-Ghani et al.
DIABETES CARE (2016)
Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial
Tomoya Mita et al.
DIABETES CARE (2016)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
Carotid Intima-Media Thickness Progression and Risk of Vascular Events in People With Diabetes: Results From the PROG-IMT Collaboration
Matthias W. Lorenz et al.
DIABETES CARE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
Kamlesh Khunti et al.
DIABETES CARE (2015)
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
Kohei Kaku et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials
Yukio Tanizawa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats
Takumi Nagata et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes A nationwide population-based study
Pai-Feng Hsu et al.
DIABETES CARE (2013)
Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data
Matthias W. Lorenz et al.
LANCET (2012)
Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice
Masayuki Suzuki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Hypoglycemia and Cardiovascular Risks
Brian M. Frier et al.
DIABETES CARE (2011)
Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis
Zachary D. Goldberger et al.
AMERICAN HEART JOURNAL (2010)
Does Carotid Intima-Media Thickness Regression Predict Reduction of Cardiovascular Events? A Meta-Analysis of 41 Randomized Trials
Pierluigi Costanzo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension
Hiroyoshi Ono et al.
HYPERTENSION RESEARCH (2008)
Progression of carotid stenosis detected by duplex ultrasonography predicts adverse outcomes in cardiovascular high-risk patients
Schila Sabeti et al.
STROKE (2007)
Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol:: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study
D. Mortsell et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Prediction of clinical cardiovascular events with carotid intima-media thickness - A systematic review and meta-analysis
Matthias W. Lorenz et al.
CIRCULATION (2007)
Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope
Toshihiko Yanase et al.
AMERICAN JOURNAL OF HYPERTENSION (2006)
Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus
Hiroki Yokoyama et al.
STROKE (2006)
Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors
MA Espeland et al.
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE (2005)
Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes
N Katakami et al.
DIABETOLOGIA (2004)
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes
K Matsumoto et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol - A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness
AJ Taylor et al.
CIRCULATION (2002)
Noninvasive tests of vascular function and structure: Why and how to perform them
R Fathi et al.
AMERICAN HEART JOURNAL (2001)
Share Paper
